10/1/07

Economics

Politics

Domestic

International War Against Radical Islam

The Market

Technical

Fundamental

I did a weekend update on our 10 Bagger List:

Medivation continues to move forward in the Dimebon trials for both Alzheimer’s and Huntington’s Disease. In the latter’s case, while I have no knowledge about the results, the current Phase I/II trial should be completed soon. In addition, the company should commence an MDV 3100 Phase I/IIa trial for prostate cancer in the near future.

I am hoping for another announcement of a new contract for ParkerVision; but nothing so far. In the meantime, ITT keeps getting contracts for its wireless systems and that means contracts for PRKR.

Raptor Network Technologies has also received some new albeit small orders. You will recall the Aggressive Growth Portfolio sold this stock during the August crunch in stock prices because the stock had hit its Stop Loss Price. The Aggressive Growth Portfolio will re-initiate this position on the Market open this morning.

Remember that these are very risky investments. Only those subscribers who can afford to lose their entire investment in these stocks should be buying them and then positions should be one third to one quarter the size of a normal position.

News on Stocks in Our Portfolios

Graco (Dividend Growth Portfolio) is buying back an additional 7 million shares

Citigroup announced that it expected to take a multibillion dollar write off related to the sub prime mortgage problem in the third quarter. I think that this is already discounted in the stock price but will be watching it closely today.

More Cash in Investors’ Hands

Bain Capital is buying 3Com for $2 billion in cash.